lenalidomide has been researched along with Lymphoma in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.00) | 29.6817 |
| 2010's | 17 (68.00) | 24.3611 |
| 2020's | 6 (24.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, J; Fukuda, T; Inamoto, Y; Ito, A; Kim, SW; Takeda, W; Tanaka, T; Watanabe, M | 1 |
| Chen, H; Duan, X; Lin, D; Liu, H; Miao, C; Nie, T; Wu, J; Zhang, X; Zheng, Y; Zhong, W | 1 |
| Lin, X; Wang, J; Wang, X; Wen, Y; Yan, X; Zhou, Y | 1 |
| Bai, JF; Feng, R; Han, HX; Li, JT; Liu, H; Wang, T; Zhang, CL | 1 |
| Li, Q; Wen, F; Xie, D; Zhang, PF | 1 |
| Kuruvilla, J | 1 |
| Arai, A; Nakayama, K; Tajika, K; Tamai, H | 1 |
| Chen, L; Chen, N; Choi, K; Damato, B; Formaker, P; Fraser, EJ; Gangoiti, J; Geng, H; Hwang, J; Killea, P; Kurhanewicz, J; Li, J; Lowell, C; Munster, PN; Rubenstein, JL; Sharma, J; Sneed, PK; Treseler, P; Ventura, J; Wang, X | 1 |
| Ansell, SM; Colgan, J; Dueck, AC; Ernst, B; Ginos, BF; Habermann, TM; Johnston, PB; Kosiorek, HE; Leis, JF; Mikhael, JR; Nowakowski, GS; Padrnos, L; Porrata, L; Reeder, C; Toro, A; Witzig, TE | 1 |
| Andre, M; Bijou, F; Bonnet, C; Bouabdallah, K; Cartron, G; Casasnovas, RO; de Guibert, S; Feugier, P; Fruchart, C; Haioun, C; Houot, R; Le Gouill, S; Maerevoet, M; Molina, L; Moluçon-Chabrot, C; Morschhauser, F; Nicolas-Virelizier, E; Ruminy, P; Salles, GA; Tilly, H; Van Den Neste, E; Van Eygen, K; Van Hoof, A; Zachee, P | 1 |
| Damato, B; Formaker, P; Geng, H; Hwang, J; Mannis, G; Munster, PN; Rubenstein, JL; Vu, K | 1 |
| Ghesquieres, H; Soussain, C | 1 |
| Bateman, S; Cha, SC; Chen, J; Kwak, LW; Lerman, B; Qin, H; Sakamaki, I; Surapaneni, S; Yi, Q | 1 |
| Cheah, CY; Forbes, SG; Fowler, NH; Nastoupil, LJ; Neelapu, SS; Oki, Y | 1 |
| Biernacka, M; Borycka, IS; Bujko, M; Błachnio, K; Grygorowicz, MA; Markowicz, S; Nowak, E; Paszkiewicz-Kozik, E; Rymkiewicz, G; Walewski, J | 1 |
| Horwitz, SM; Mehta-Shah, N | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Brady, HA; Chan, KW; Escoubet-Lozach, L; Gandhi, AK; Jensen-Pergakes, K; Lin, IL; Muller, GW; Schafer, PH; Verhelle, D; Worland, PJ | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Schmidt-Hieber, M; Thiel, E; Weimann, A | 1 |
| Alpmann, P; Blaum-Feder, S; Carson, D; Endo, T; Kim, Y; Krämer, S; Lu, D; Schmidt-Wolf, IG | 1 |
| Agliano, A; Bertolini, F; Calleri, A; Calvo, A; Gregato, G; Marighetti, P; Martin-Padura, I; Prior, C; Redrado, M | 1 |
| Lentzsch, S; Pan, B | 1 |
| Ogura, M | 1 |
| Wiernik, PH | 1 |
3 review(s) available for lenalidomide and Lymphoma
| Article | Year |
|---|---|
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide | 2012 |
Lenalidomide in lymphomas and chronic lymphocytic leukemia.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Thalidomide | 2013 |
5 trial(s) available for lenalidomide and Lymphoma
| Article | Year |
|---|---|
Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.
Topics: Aged; Central Nervous System Neoplasms; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma; Maintenance Chemotherapy; Male; Middle Aged; Recurrence; Rituximab; Survival Rate | 2018 |
A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Everolimus; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma; Male; Maximum Tolerated Dose; Mechanistic Target of Rapamycin Complex 1; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence | 2019 |
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Purines; Quinazolinones; Rituximab; Thalidomide | 2015 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
17 other study(ies) available for lenalidomide and Lymphoma
| Article | Year |
|---|---|
Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation.
Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Recurrence; Retrospective Studies | 2023 |
Cerebral delivery of redox-responsive lenalidomide prodrug plus methotrexate for primary central nerve system lymphoma combination therapy.
Topics: Brain Neoplasms; Central Nervous System Neoplasms; Humans; Lenalidomide; Lymphoma; Methotrexate; Oxidation-Reduction; Prodrugs | 2023 |
Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report.
Topics: Agammaglobulinaemia Tyrosine Kinase; Central Nervous System; HIV; HIV Infections; Humans; Lenalidomide; Lymphoma | 2023 |
[Lenalidomide, rituximab and dexamethasone for the treatment of recurrent/refractory or elderly newly diagnosed patients with primary central nervous system lymphoma: 5 cases report and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dexamethasone; Humans; Lenalidomide; Lymphoma; Neoplasm Recurrence, Local; Rituximab; Treatment Outcome | 2019 |
Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Lymphoma; Male; Rituximab | 2020 |
Developing anti-CD19 antibody-based combinations in lymphoma.
Topics: Antigens, CD19; Humans; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Prospective Studies | 2020 |
Treatment of relapsed aggressive adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation with mogamulizumab followed by lenalidomide.
Topics: Antibodies, Monoclonal, Humanized; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma | 2021 |
Phase 1 clinical trials and toxicity.
Topics: Humans; Lenalidomide; Lymphoma; Medical Oncology; Purines; Quinazolinones; Rituximab | 2017 |
Maintenance lenalidomide in primary CNS lymphoma.
Topics: Humans; Intraocular Lymphoma; Lenalidomide; Lymphoma; Neoplasm Recurrence, Local; Prospective Studies; Rituximab | 2019 |
Reply to the letter to the editor 'Maintenance lenalidomide in primary CNS lymphoma' by Rubenstein et al.
Topics: Humans; Intraocular Lymphoma; Lenalidomide; Lymphoma; Prospective Studies; Rituximab | 2019 |
Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas.
Topics: Animals; Antibodies; Antibody Specificity; Antineoplastic Agents; Cancer Vaccines; Disease Models, Animal; Female; Humans; Immunologic Factors; Immunologic Memory; Lenalidomide; Lymphoma; Mice; T-Lymphocyte Subsets; Thalidomide; Tumor Burden | 2014 |
Lenalidomide potentiates CD4
Topics: Adult; Aged; B-Lymphocytes; Blood Donors; CD4 Antigens; Cell Proliferation; Cells, Cultured; Female; Humans; Immunologic Factors; Interleukin-2 Receptor alpha Subunit; Lenalidomide; Lymphoma; Male; Middle Aged; Sirolimus; T-Lymphocytes, Regulatory; Thalidomide | 2017 |
Lenalidomide in Adult T-Cell Leukemia/Lymphoma.
Topics: Adult; Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Thalidomide; Treatment Outcome | 2016 |
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatin; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Neoplastic; Histone Demethylases; Histones; Humans; Lenalidomide; Lymphoma; Multiple Myeloma; Oxidoreductases, N-Demethylating; Thalidomide; Transcription Factors | 2009 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; K562 Cells; Ki-67 Antigen; Lenalidomide; Leukemia, Myeloid; Lymphoma; Multiple Myeloma; Phosphorylcholine; Pyrazines; Thalidomide; Time Factors | 2012 |
In vivo efficacy of griseofulvin against multiple myeloma.
Topics: Animals; Antifungal Agents; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Ciclopirox; Griseofulvin; Humans; Immunosuppressive Agents; Lenalidomide; Lymphoma; Mice; Mice, Inbred BALB C; Multiple Myeloma; Pyridones; Signal Transduction; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm.
Topics: Animals; Antineoplastic Agents; Dendritic Cells; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Killer Cells, Natural; Lenalidomide; Lymphoma; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Thalidomide; Transplantation, Heterologous | 2011 |